Shattuck Labs, Inc.
STTKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeShattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The $652.4M market capitalization puts STTK squarely in small-cap range for its industry. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Market Cap
$652.4M
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
-12.39
EPS (TTM)
$-0.44
EPS (Fwd)
$-0.52
ROE
-39.2%
ROA
-24.4%
Cash
$208.3M
Total Debt
$2.7M
Free CF
-$21.2M
52W Change
288.0%
Annual Financials
Cash vs Debt
Where STTK stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, STTK finished 12.25% above its 150-day moving average ($6.12) and 26.99% above its 200-day moving average ($5.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STTK overbought or oversold?
At the September 2, 2026 close, STTK's RSI(14) was 39.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Shattuck Labs, Inc. holds $208.3M in cash against $2.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$21.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -39.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $652K (2022) to $1.0M (2025), reflecting a 53% increase over the period.
With cash comfortably exceeding debt, STTK has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Shattuck Labs, Inc.'s trajectory.